FY2029 EPS Forecast for ImmunityBio Increased by Analyst

ImmunityBio, Inc. (NASDAQ:IBRX) – HC Wainwright upped their FY2029 EPS estimates for ImmunityBio in a report issued on Wednesday, November 5th. HC Wainwright analyst A. Maldonado now expects that the company will post earnings of $0.41 per share for the year, up from their previous forecast of $0.34. HC Wainwright currently has a “Buy” rating and a $8.00 price target on the stock. The consensus estimate for ImmunityBio’s current full-year earnings is ($0.92) per share.

ImmunityBio (NASDAQ:IBRX) last announced its quarterly earnings results on Tuesday, August 5th. The company reported ($0.10) earnings per share for the quarter, meeting the consensus estimate of ($0.10). The firm had revenue of $26.43 million for the quarter, compared to analysts’ expectations of $21.95 million.

Other analysts have also issued reports about the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of ImmunityBio in a report on Wednesday. D. Boral Capital reaffirmed a “buy” rating and set a $24.00 price target on shares of ImmunityBio in a research report on Wednesday. Four equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $10.75.

ImmunityBio Stock Up 0.5%

Shares of ImmunityBio stock opened at $2.13 on Friday. The company’s fifty day simple moving average is $2.48 and its two-hundred day simple moving average is $2.58. ImmunityBio has a 12-month low of $1.83 and a 12-month high of $5.88. The firm has a market cap of $2.10 billion, a PE ratio of -5.20 and a beta of 0.29.

Institutional Trading of ImmunityBio

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Slow Capital Inc. bought a new stake in ImmunityBio during the 3rd quarter valued at approximately $25,000. Truist Financial Corp bought a new position in shares of ImmunityBio in the 3rd quarter worth approximately $27,000. Diversify Advisory Services LLC purchased a new position in shares of ImmunityBio in the 2nd quarter valued at approximately $27,000. Financial Enhancement Group LLC bought a new stake in shares of ImmunityBio during the second quarter valued at approximately $28,000. Finally, Summit X LLC bought a new stake in shares of ImmunityBio during the second quarter valued at approximately $28,000. 8.58% of the stock is currently owned by hedge funds and other institutional investors.

ImmunityBio Company Profile

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.